Volume 8, Number 4—April 2002
Research
Laboratory Reporting of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in United States Department of Veterans Affairs Facilities1
Stephen M. Kralovic*†‡
, Linda H. Danko*†, and Gary A. Roselle*†‡
, Linda H. Danko*†, and Gary A. Roselle*†‡Table 3
Reported susceptibility to quinolones and other agents of reported isolates of Staphylococcus aureus with reduced susceptibility to vancomycin from United States Veterans Health Administration medical facilities, FFY 1999a
| Case | MIC/sensitivity status | |||||
|---|---|---|---|---|---|---|
| ciprofloxacin | levofloxacin | ofloxacin | norfloxacin | gentamicin | furodantin | |
| 1 | /S | |||||
| 2 | <1 μg/mL | <4 μg/mL | <1 μg/mL | <32 μg/mL | ||
| 3 | >2 μg/mL/R | >4 μg/mL/R | >8 μg/mL | <1 μg/mL | <32 μg/mL | |
| 4 | >2 μg/mL/R | >8 μg/mL | <1 μg/mL | <32 μg/mL | ||
| 5 | <1 μg/mL/S | 4 μg/mL/I | <1 μg/mL/S | |||
| 6 | >2 μg/mL/R | >4 μg/mL/R | 8 μg/mL/I | |||
| 7 | >2 μg/mL/R | >4 μg/mL/R | >8 μg/mL/R | |||
| 8 | >2 μg/mL/R | >4 μg/mL/R | >8 μg/mL/R | |||
| 9 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL | ||
| 10 | =2 μg/mL/I | <2 μg/mL/S | <1 μg/mL/S | =64 μg/mL | ||
| 11 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL | ||
| 12 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL/S | ||
| 13 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL/S | ||
| 14 | <1 μg/mL/S | <2 μg/mL/S | <1 μg/mL/S | <32 μg/mL | ||
| 15 | /R | |||||
| 16 | ||||||
| 17 | ||||||
| 18 | <1 μg/mL | <1 μg/mL | ||||
| 19 | <0.5 μg/mL/S | <1 μg/mL/S | <2 μg/mL/S | |||
| Total | 9/16=R | 4/5=R | 4/7=R | 3/16=R | ||
aFFY=Federal fiscal year; S=susceptible, I=intermediate and R=resistant based on laboratory interpretative criteria.
1A portion of this material was presented at the 11th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America in Toronto, Ontario, Canada (Abstract #49), April 2001.
